Scientists May Have Put Microbes in a State of Quantum Entanglement

Hall of Mirrors

A few years ago, the journal Small published a study showing how photosynthetic bacteria could absorb and release photons as the light bounced across a minuscule gap between two mirrors.

Now, a retroactive look at the study’s data published in The Journal of Physics Communications suggests something more may have been going on. The bacteria may have been the first living organisms to operate in the realm of quantum physics, becoming entangled with the bouncing light at the quantum scale.

Cat’s Cradle

The experiment in question, as described by Scientific American, involved individual photons — the smallest quantifiable unit of light that can behave like a tiny particle but also a wave of energy within quantum physics — bouncing between two mirrors separated by a microscopic distance.

But a look at the energy levels in the experimental setup suggests that the bacteria may have become entangled, as some individual photons seem to have simultaneously interacted with and missed the bacterium at the same time.

Super Position

There’s reason to be skeptical of these results until someone actually recreates the experiment while looking for signs of quantum interactions. As with any look back at an existing study, scientists are restricted to the amount and quality of data that was already published. And, as Scientific American noted, the energy levels of the bacteria and the mirror setup should have been recorded individually — which they were not — in order to verify quantum entanglement.

But if this research holds up, it would be the first time a life form operated on the realm of quantum physics, something usually limited to subatomic particles. And even though the microbes are small, that’s a big deal.

READ MORE“Schrödinger’s Bacterium” Could Be a Quantum Biology Milestone [Scientific American]

More on quantum physics: The World’s First Practical Quantum Computer May Be Just Five Years Away

Read more from the original source:

Scientists May Have Put Microbes in a State of Quantum Entanglement

There’s No Way China’s Artificial Moon Will Work, Says Expert

Good Luck

On October 10, a Chinese organization called the Tian Fu New Area Science Society revealed plans to replace the streetlights in the city of Chengdu with a satellite designed to reflect sunlight toward the Earth’s surface at night.

But in a new interview with Astronomy, an associate professor of aerospace engineering at the University of Texas at Austin named Ryan Russel argued that based on what he’s read, the artificial moon plan would be impossible to implement.

Promised the Moon

Wu Chunfeng, the head of the Tian Fu New Area Science Society, told China Daily the artificial moon would orbit about 310 miles above Earth, delivering an expected brightness humans would perceive to be about one-fifth that of a typical streetlight.

The plan is to launch one artificial moon in 2020 and then three more in 2022 if the first works as hoped. Together, these satellites could illuminate an area of up to 4,000 square miles, Chunfeng claims.

But Russell is far from convinced.

“Their claim for 1 [low-earth orbit satellite] at [300 miles] must be a typo or misinformed spokesperson,” he told Astronomy. “The article I read implied you could hover a satellite over a particular city, which of course is not possible.”

Overkill Overhead

To keep the satellite in place over Chengdu, it would need to be about 22,000 miles above the Earth’s surface, said Russel, and its reflective surface would need to be massive to reflect sunlight from that distance. At an altitude of just 300 miles, the satellite would quickly zip around the Earth, constantly illuminating new locations.

Even if the city could put the artificial moon plan into action, though, Russell isn’t convinced it should.

“It’s a very complicated solution that affects everyone to a simple problem that affects a few,” he told Astronomy. “It’s light pollution on steroids.”

Maybe Chengdu shouldn’t give up on its streetlights just yet.

READ MORE: Why China’s Artificial Moon Probably Won’t Work [Astronomy]

More on the artificial moon: A Chinese City Plans to Replace Its Streetlights With an Artificial Moon

See the article here:

There’s No Way China’s Artificial Moon Will Work, Says Expert

Clean Coal Startup Turns Human Waste Into Earth-Friendly Fuel

Gold Nuggets

A company called Ingelia says it’s figured out a way to turn human waste — the solid kind — into a combustible material it’s calling biochar. And if Ingelia’s claims are accurate, biochar can be burned for fuel just like coalexcept with nearzero greenhouse gas emissions, according to Business Insider.

That’s because almost all of the pollutants and more harmful chemicals that would normally be given off while burning solid fuels is siphoned away into treatable liquid waste, leaving a dry, combustible rod of poop fuel.

“Clean Coal

Ingelia, which is currently working to strike a deal with Spanish waste management facilities, hopes to make enough biochar to replace 220 thousand tons of coal per year, corresponding to 500 thousand tons of carbon dioxide emissions.

But that’s by 2022, at which point we’ll have even less time to reach the urgent clean energy goals of that doomsday United Nations report. In an ideal world, we would have moved away from coal years ago. At least this gives us a viable alternative as we transition to other, renewable forms of electricity.

So while we can, in part, poop our way to a better world, biochar — and other new sewage-based energy sources — will only be one of many new world-saving sources of clean energy.

READ MORE: This Spanish company found a way to produce a fuel that emits no CO2 — and it’s made of sewage [Business Insider]

More on poop: Edible Tech is Finally Useful, is Here to Help you Poop

Follow this link:

Clean Coal Startup Turns Human Waste Into Earth-Friendly Fuel

Ford’s Self-Driving Cars Are About to Chauffeur Your Senator

Green-Light District

It doesn’t matter how advanced our self-driving cars get — if they aren’t allowed on roads, they aren’t going to save any lives.

The future of autonomous vehicles (AVs) in the U.S. depends on how lawmakers in Washington D.C. choose to regulate the vehicles. But until now, AV testing has largely taken place far from the nation’s capital, mostly in California and Arizona.

Ford is about to change that. The company just announced plans to be the first automaker to test its self-driving cars in the Distinct of Columbia — and how lawmakers feel about those vehicles could influence future AV legislation.

Career Day

Sherif Marakby, CEO of Ford Autonomous Vehicles, announced the decision to begin testing in D.C. via a blog post last week. According to Marakby, Ford’s politician-friendly focus will be on figuring out how its AVs could promote job creation in the District.

To that end, Ford plans to assess how AVs could increase mobility in D.C., thereby helping residents get to jobs that might otherwise be outside their reach, as well as train residents for future positions as AV technicians or operators.

Up Close and Personal

Marakby notes that D.C. is a particularly suitable location for this testing because the District is usually bustling with activity. The population increases significantly during the day as commuters arrive from the suburbs for work, while millions of people flock to D.C. each year for conferences or tourism.

D.C. is also home to the people responsible for crafting and passing AV legislation. “[I]t’s important that lawmakers see self-driving vehicles with their own eyes as we keep pushing for legislation that governs their safe use across the country,” Marakby wrote.

Ford’s ultimate goal is to launch a commercial AV service in D.C. in 2021. With this testing, the company has the opportunity to directly influence the people who could help it reach that goal — or oppose it.

READ MORE: A Monumental Moment: Our Self-Driving Business Development Expands to Washington, D.C. [Medium]

More on AV legislation: U.S. Senators Reveal the Six Principles They’ll Use to Regulate Self-Driving Vehicles

Continue reading here:

Ford’s Self-Driving Cars Are About to Chauffeur Your Senator

This AI Lie Detector Flags Falsified Police Reports

Minority Report

Imagine this: You file a police report, but back at the station, they feed it into an algorithm — and it accuses you of lying, as though it had somehow looked inside your brain.

That might sound like science fiction, but Spain is currently rolling out a very similar program, called VeriPol, in many of its police stations. VeriPol’s creators say that when it flags a report as false, it turns out to be correct more than four-fifths of the time.

Lie Detector

VeriPol is the work of researchers at Cardiff University and Charles III University of Madrid.

In a paper published earlier this year in the journal Knowledge-Based Systems, they describe how they trained the lie detector with a data set of more than 1,000 robbery reports — including a number that police identified as false — to identify subtle signs that a report wasn’t true.

Thought Crime

In pilot studies in Murcia and Malaga, Quartz reported, further investigation showed that the algorithm was correct about 83 percent of the time that it suspected a report was false.

Still, the project raises uncomfortable questions about allowing algorithms to act as lie detectors. Fast Company reported earlier this year that authorities in the United States, Canada, and the European Union are testing a separate system called AVATAR that they want to use to collect biometric data about subjects at border crossings — and analyze it for signs that they’re not being truthful.

Maybe the real question isn’t whether the tech works, but whether we want to permit authorities to act upon what’s essentially a good — but not perfect — assumption that someone is lying.

READ MORE: Police Are Using Artificial Intelligence to Spot Written Lies [Quartz]

More on lie detectors: Stormy Daniels Took a Polygraph. What Do We Do With the Results?

Read more from the original source:

This AI Lie Detector Flags Falsified Police Reports

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Latest Releases:

View Scientific Abstract Oral and Poster Presentations from SNMMI’s2018 Annual Meeting.Learn More

Access synchronized slides, audio and embedded video from 100 of the most popular sessions from SNMMIs 2018 Annual Meeting.Learn More

The new Radiation Safety+ Review and Essentials program provides a comprehensive overview of all aspects of radiation safety for nuclear medicine technologists preparing to take the NMTCBs Radiation Safety Certification Examination.Learn More

CT+ Review and Essentials provides you with the comprehensive didactic education you need to succeed, whether you’re looking to buildyour general CT knowledge, or preparing to sit for the ARRT (CT) and/or NMTCB (CT) exam(s).Learn More

SNMMI’s online nuclear medicine review course coversadult and pediatric medicine, PET/CT and nuclear cardiology plus imaging protocols, interpretation and limitation.Learn More

SNMMI/ACNM MRI Case Reviews: AbdominalSNMMI and ACNM have partnered to bring you the first-ever set of online MRI teaching modules as an introduction to interpreting MRI.Learn More

Mid-Winter Meeting CT Case ReviewsThis offering provides a comprehensiveCT Case Reviewfor nuclear medicine professionals. Review and interpret up to 100 CT studies.Learn More

Annual Meeting CT/MRI Case ReviewsRecorded at the Annual Meeting, this online offering provides the opportunity to review and interpret 52 CT studies and 48 MRI case studies.Learn More

Free Journal SAM/CE accessis available exclusively for SNMMI Members. Take advantage of this great benefit and meet your certification requirements.Learn more

Fee recently reduced! The PET Online Review Workshop is designed to prepare technologists for the NMTCB’s PET Exam.Learn More

View post:

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Molecular medicine – Wikipedia

Molecular medicine is a broad field, where physical, chemical, biological, bioinformatics and medical techniques are used to describe molecular structures and mechanisms, identify fundamental molecular and genetic errors of disease, and to develop molecular interventions to correct them.[1] The molecular medicine perspective emphasizes cellular and molecular phenomena and interventions rather than the previous conceptual and observational focus on patients and their organs.[2]

In November 1949, with the seminal paper, “Sickle Cell Anemia, a Molecular Disease”,[3] in Science magazine, Linus Pauling, Harvey Itano and their collaborators laid the groundwork for establishing the field of molecular medicine.[4] In 1956, Roger J. Williams wrote Biochemical Individuality,[5] a prescient book about genetics, prevention and treatment of disease on a molecular basis, and nutrition which is now variously referred to as individualized medicine[6] and orthomolecular medicine.[7] Another paper in Science by Pauling in 1968,[8] introduced and defined this view of molecular medicine that focuses on natural and nutritional substances used for treatment and prevention.

Published research and progress was slow until the 1970s’ “biological revolution” that introduced many new techniques and commercial applications.[9]

Some researchers separate molecular surgery as a compartment of molecular medicine.[10]

Molecular medicine is a new scientific discipline in European universities.[citation needed] Combining contemporary medical studies with the field of biochemistry, it offers a bridge between the two subjects. At present only a handful of universities offer the course to undergraduates. With a degree in this discipline the graduate is able to pursue a career in medical sciences, scientific research, laboratory work and postgraduate medical degrees.

Core subjects are similar to biochemistry courses and typically include gene expression, research methods, proteins, cancer research, immunology, biotechnology and many more. In some universities molecular medicine is combined with another discipline such as chemistry, functioning as an additional study to enrich the undergraduate program.

Read the original post:

Molecular medicine – Wikipedia

Home | Cellular & Molecular Medicine

Sara Parker, PhD a CMM postdoctoral scholar in Dr. Gus Mouneimnes lab – together with colleagues in the departments of Neuroscience, Pharmacology, an Immunobiology have recently published a new study in the journal eNeuro entitled High Fidelity Cryopreservation and Recovery of Primary Rodent Cortical Neurons”. Cryopreservation is the process of freezing biological materials, and is used routinely for the storage of cell lines. Certain cells, however, are extremely sensitive to cryostorage, and cannot be frozen such as primary neurons isolated from mouse or rat embryos, which show extremely poor viability when subjected to standard cryopreservation methodologies. Dr. Parker and colleagues, experimenting with a specialty cryopreservation reagent designed for clinical-grade storage of human stem and primary cells, found that this reagent substantially improved the viability of cryopreserved neurons, yielding cells that were indistinguishable from freshly dissected neurons. This experimental tool not only improves efficiency and maximizes utilization of animal-sourced materials, it also facilitates greater collaboration between laboratories.

Follow this link:

Home | Cellular & Molecular Medicine

Molecular Medicine – Graduate School of Biomedical …

The Department of Molecular Medicine in the Institute of Biotechnology (IBT) was established in 1994 to administer a program to train graduate students at the interface of basic and clinical sciences with an emphasis on biomedical research focused on discovering the molecular mechanisms underlying human disease and to serve as a platform for the development of novel treatment or prevention approaches. To date, our program has awarded over 120 doctoral degrees. Our graduates are placed in top-tier research universities and pharmaceutical companies across the United States and Europe. Our faculty have been successful in securing tens of millions of dollars from private and federal agencies including the National Institutes of Health, the National Science Foundation, and the Department of Defense.

Now also located in the South Texas Research Facility (STRF), we offer a research-oriented, interdisciplinary program of study in the areas of cancer and aging and their prevention. Specific areas of study include: cell (and hormone) signaling, gene expression, epigenetics, cell cycle and checkpoint controls, DNA damage repair and associated stress responses, and regulated protein turnover. Under new leadership, Dr. Tim Huang is expanding our research to include a Systems approach to molecular medicine that offers students an integrated training program spanning molecular and cellular biology, quantitative biology, computational biology, and genomics.

Our goal is to educate and train the next generation of graduate students who will change the face of biomedical research and invent new ways to treat and prevent human diseases.

Molecular Medicine in the News

Graduate School Launches a New Masters in Personalized Molecular Medicine

The Masters program in Personalized Molecular Medicine (PMM) will uniquely position new graduates to join the work force with the skills necessary to participate fully in the next generation of patient-powered research and treatment. The PMM program will train students in current personalized medicine approaches as well as teach students the knowledge and skills required to explore molecular medicine pathways that will be targeted in the future to expand and refine personalized treatment strategies.

For more information, click here.

Dr. Thomas Boyer awarded NIH grants to study uterine fibroids

Thomas G. Boyer, Ph.D., professor of molecular medicine at UT Health San Antonio, has received two related NIH R01 grants to study uterine leiomyomas, also called uterine fibroids.

The first grant was for $1.56 million; the most recent, a five-year award for $3.8 million, was a multi-PI grant to Dr. Boyer and Ayman Al-Hendy, M.D., Ph.D., a professor of obstetrics and gynecology at the University of Illinois at Chicago.

Both awards have been made possible by a productive, ongoing collaboration with Dr. Robert Schenken and his team in the Department of OB/GYN here at UT Health San Antonio, said Dr. Boyer.

For the rest of this story, please click here.

Uncovering clues in BRCA1 breast cancer gene

Dr. Rong Li and his colleagues are changing the paradigm of how BRCA1 suppresses tumors

When Rong Li, Ph.D., transferred his laboratory to UT Health San Antonio, he finally felt he was making real progress in breast cancer research.

I was trained as a molecular biologist, and I studied the fundamental cellular processes in a lab setting, says Li, a professor of molecular medicine who left his faculty position at the University of Virginia in 2007. But I felt unsatisfied because I wanted to connect my lab findings more closely to human health.

At UT Health, he found the opportunity to collaborate with physician scientists, both at the international level and closer to home. UT Health breast oncologists Ismail Jatoi, M.D., and Richard Elledge, M.D., as well as plastic and reconstructive surgeon Dr. Howard Wang, M.D., have offered cross-disciplinary support, and some of their patients donate breast tissue samples for Lis research.

The story is continued here.

Recent Publications with High Impact Factors

*L. Hulea, *S.P. Gravel, *M. Morita, M. Cargnello, O. Uchenunu, Y.K. Im, C. Lehud, E.H. Ma, M. Leibovitch, S. McLaughlan, M.J. Blouin, M. Parisotto, V. Papavasiliou, C. Lavoie, O. Larsson, M. Ohh, T. Ferreira, C. Greenwood, G. Bridon, D. Avizonis, G. Ferbeyre, P. Siegel, R.G. Jones, W. Muller, J. Ursini-Siegel, J. St-Pierre, M. Pollak, I. Topisirovic. (2018) Translational and HIF-1-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides, Cell Metabolism. 2018 September 20. Online. *Co-First authors.

Seol JH, Holland C, Li X, Kim C, Li F, Medina-Rivera M, Eichmiller R, Gallardo IF, Finkelstein IJ, Hasty P, Shim EY, Surtees JA, Lee SE. (2018) Distinct roles of XPF-ERCC1 and Rad1-Rad10-Saw1 in replication-coupled and uncoupled inter-strand crosslink repair. Nat Commun. 2018 May 23;9(1):2025. doi:10.1038/s41467-018-04327-0. PubMed PMID: 29795289.

Patel MJ, Tripathy S, De Mukhopadhyay K, Wangjam T, Cabang AB, Morris J, Wargovich MJ. (2018) A Supercritical Co2 Extract of Neem Leaf (A. indica) and its Bioactive Liminoid, Nimbolide, Suppresses Colon Cancer in Preclinical Models by Modulating Pro-inflammatory Pathways. Mol Carcinogenesis. 2018 Apr 26. doi: 10.1002/mc.22832. [Epub ahead of print] PMID: 29697164

Park MJ, Shen H, Spaeth JM, Tolvanen JH, Failor C, Knudtson JF, McLaughlin J, Halder SK, Yang Q, Bulun SE, Al-Hendy A, Schenken RS, Aaltonen LA, Boyer TG. (2018) Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19. J Biol Chem. 2018 Mar 30; 293(13):4870-4882. doi: 10.1074/jbc.RA118.001725. Epub 2018 Feb 13.

Chen H, Shen F, Sherban A, Nocon A, Li Y, Wang H, Xu MJ, Rui X, Han J, Jiang B, Lee D, Li N, Keyhani-Nejad F, Fan JG, Liu F, Kamat A, Musi N, Guarente L, Pacher P, Gao B, Zang M. (2018) DEP domain-containing mTOR-interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute-on-chronic liver injury in alcoholic liver disease. Hepatology. 2018 Feb 19. doi: 10.1002/hep.29849. [Epub ahead of print]

Recently Awarded Grants

Early Detection of Castration-Resistant Prostate Cancer by Assessing Interactions Between Circulating Tumor Cells and Accompanying Immune CellsDOD (CDMRP-PCRP), 9/1/18, $915,000Tim Huang, Ph.D., Maria Gaczynska, Ph.D.

Mechanisms of Error Prone Repair of DNA breaksNIH – National Institute of General Medical Sciences, 8/1/18, $1,250,500Sang Eun Lee, Ph.D.

2018 Young Investigator AwardThe Max and Minnie Tomerlin Voelcker Fund, 6/30/2018, $450,000Myron Ignatius, Ph.D.

Combating protein-misfolding diseasesWilliam & Ella Owens Foundation of America, 3/1/18, $100,000Hai Rao, Ph.D.

Hypovitaminosis D promotes MED12-associated genomic instability in uterine fibroidsNIH National Institute of Child Health and Human Development, 2/15/18, $3,819,365Thomas Boyer, Ph.D.

More:

Molecular Medicine – Graduate School of Biomedical …

Molecular medicine – Wikipedia

Molecular medicine is a broad field, where physical, chemical, biological, bioinformatics and medical techniques are used to describe molecular structures and mechanisms, identify fundamental molecular and genetic errors of disease, and to develop molecular interventions to correct them.[1] The molecular medicine perspective emphasizes cellular and molecular phenomena and interventions rather than the previous conceptual and observational focus on patients and their organs.[2]

In November 1949, with the seminal paper, “Sickle Cell Anemia, a Molecular Disease”,[3] in Science magazine, Linus Pauling, Harvey Itano and their collaborators laid the groundwork for establishing the field of molecular medicine.[4] In 1956, Roger J. Williams wrote Biochemical Individuality,[5] a prescient book about genetics, prevention and treatment of disease on a molecular basis, and nutrition which is now variously referred to as individualized medicine[6] and orthomolecular medicine.[7] Another paper in Science by Pauling in 1968,[8] introduced and defined this view of molecular medicine that focuses on natural and nutritional substances used for treatment and prevention.

Published research and progress was slow until the 1970s’ “biological revolution” that introduced many new techniques and commercial applications.[9]

Some researchers separate molecular surgery as a compartment of molecular medicine.[10]

Molecular medicine is a new scientific discipline in European universities.[citation needed] Combining contemporary medical studies with the field of biochemistry, it offers a bridge between the two subjects. At present only a handful of universities offer the course to undergraduates. With a degree in this discipline the graduate is able to pursue a career in medical sciences, scientific research, laboratory work and postgraduate medical degrees.

Core subjects are similar to biochemistry courses and typically include gene expression, research methods, proteins, cancer research, immunology, biotechnology and many more. In some universities molecular medicine is combined with another discipline such as chemistry, functioning as an additional study to enrich the undergraduate program.

View original post here:

Molecular medicine – Wikipedia

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Latest Releases:

View Scientific Abstract Oral and Poster Presentations from SNMMI’s2018 Annual Meeting.Learn More

Access synchronized slides, audio and embedded video from 100 of the most popular sessions from SNMMIs 2018 Annual Meeting.Learn More

The new Radiation Safety+ Review and Essentials program provides a comprehensive overview of all aspects of radiation safety for nuclear medicine technologists preparing to take the NMTCBs Radiation Safety Certification Examination.Learn More

CT+ Review and Essentials provides you with the comprehensive didactic education you need to succeed, whether you’re looking to buildyour general CT knowledge, or preparing to sit for the ARRT (CT) and/or NMTCB (CT) exam(s).Learn More

SNMMI’s online nuclear medicine review course coversadult and pediatric medicine, PET/CT and nuclear cardiology plus imaging protocols, interpretation and limitation.Learn More

SNMMI/ACNM MRI Case Reviews: AbdominalSNMMI and ACNM have partnered to bring you the first-ever set of online MRI teaching modules as an introduction to interpreting MRI.Learn More

Mid-Winter Meeting CT Case ReviewsThis offering provides a comprehensiveCT Case Reviewfor nuclear medicine professionals. Review and interpret up to 100 CT studies.Learn More

Annual Meeting CT/MRI Case ReviewsRecorded at the Annual Meeting, this online offering provides the opportunity to review and interpret 52 CT studies and 48 MRI case studies.Learn More

Free Journal SAM/CE accessis available exclusively for SNMMI Members. Take advantage of this great benefit and meet your certification requirements.Learn more

Fee recently reduced! The PET Online Review Workshop is designed to prepare technologists for the NMTCB’s PET Exam.Learn More

Continue reading here:

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Home | Cellular & Molecular Medicine

Sara Parker, PhD a CMM postdoctoral scholar in Dr. Gus Mouneimnes lab – together with colleagues in the departments of Neuroscience, Pharmacology, an Immunobiology have recently published a new study in the journal eNeuro entitled High Fidelity Cryopreservation and Recovery of Primary Rodent Cortical Neurons”. Cryopreservation is the process of freezing biological materials, and is used routinely for the storage of cell lines. Certain cells, however, are extremely sensitive to cryostorage, and cannot be frozen such as primary neurons isolated from mouse or rat embryos, which show extremely poor viability when subjected to standard cryopreservation methodologies. Dr. Parker and colleagues, experimenting with a specialty cryopreservation reagent designed for clinical-grade storage of human stem and primary cells, found that this reagent substantially improved the viability of cryopreserved neurons, yielding cells that were indistinguishable from freshly dissected neurons. This experimental tool not only improves efficiency and maximizes utilization of animal-sourced materials, it also facilitates greater collaboration between laboratories.

More here:

Home | Cellular & Molecular Medicine

Molecular medicine – Wikipedia

Molecular medicine is a broad field, where physical, chemical, biological, bioinformatics and medical techniques are used to describe molecular structures and mechanisms, identify fundamental molecular and genetic errors of disease, and to develop molecular interventions to correct them.[1] The molecular medicine perspective emphasizes cellular and molecular phenomena and interventions rather than the previous conceptual and observational focus on patients and their organs.[2]

In November 1949, with the seminal paper, “Sickle Cell Anemia, a Molecular Disease”,[3] in Science magazine, Linus Pauling, Harvey Itano and their collaborators laid the groundwork for establishing the field of molecular medicine.[4] In 1956, Roger J. Williams wrote Biochemical Individuality,[5] a prescient book about genetics, prevention and treatment of disease on a molecular basis, and nutrition which is now variously referred to as individualized medicine[6] and orthomolecular medicine.[7] Another paper in Science by Pauling in 1968,[8] introduced and defined this view of molecular medicine that focuses on natural and nutritional substances used for treatment and prevention.

Published research and progress was slow until the 1970s’ “biological revolution” that introduced many new techniques and commercial applications.[9]

Some researchers separate molecular surgery as a compartment of molecular medicine.[10]

Molecular medicine is a new scientific discipline in European universities.[citation needed] Combining contemporary medical studies with the field of biochemistry, it offers a bridge between the two subjects. At present only a handful of universities offer the course to undergraduates. With a degree in this discipline the graduate is able to pursue a career in medical sciences, scientific research, laboratory work and postgraduate medical degrees.

Core subjects are similar to biochemistry courses and typically include gene expression, research methods, proteins, cancer research, immunology, biotechnology and many more. In some universities molecular medicine is combined with another discipline such as chemistry, functioning as an additional study to enrich the undergraduate program.

Read the original here:

Molecular medicine – Wikipedia

Molecular Medicine | USF Health

Our Mission

To Discover, apply and disseminate knowledge of the molecular basis of health and disease.

To Translate, this knowledge into innovative tools for the diagnosis, treatment and prevention of disease.

To Train, and mentor future scientists and health care professionals.

To Provide, a collegial and scholarly environment where students, faculty and staff thrive.

Read the original:

Molecular Medicine | USF Health

Molecular Medicine – Graduate School of Biomedical …

The Department of Molecular Medicine in the Institute of Biotechnology (IBT) was established in 1994 to administer a program to train graduate students at the interface of basic and clinical sciences with an emphasis on biomedical research focused on discovering the molecular mechanisms underlying human disease and to serve as a platform for the development of novel treatment or prevention approaches. To date, our program has awarded over 120 doctoral degrees. Our graduates are placed in top-tier research universities and pharmaceutical companies across the United States and Europe. Our faculty have been successful in securing tens of millions of dollars from private and federal agencies including the National Institutes of Health, the National Science Foundation, and the Department of Defense.

Now also located in the South Texas Research Facility (STRF), we offer a research-oriented, interdisciplinary program of study in the areas of cancer and aging and their prevention. Specific areas of study include: cell (and hormone) signaling, gene expression, epigenetics, cell cycle and checkpoint controls, DNA damage repair and associated stress responses, and regulated protein turnover. Under new leadership, Dr. Tim Huang is expanding our research to include a Systems approach to molecular medicine that offers students an integrated training program spanning molecular and cellular biology, quantitative biology, computational biology, and genomics.

Our goal is to educate and train the next generation of graduate students who will change the face of biomedical research and invent new ways to treat and prevent human diseases.

Molecular Medicine in the News

Graduate School Launches a New Masters in Personalized Molecular Medicine

The Masters program in Personalized Molecular Medicine (PMM) will uniquely position new graduates to join the work force with the skills necessary to participate fully in the next generation of patient-powered research and treatment. The PMM program will train students in current personalized medicine approaches as well as teach students the knowledge and skills required to explore molecular medicine pathways that will be targeted in the future to expand and refine personalized treatment strategies.

For more information, click here.

Dr. Thomas Boyer awarded NIH grants to study uterine fibroids

Thomas G. Boyer, Ph.D., professor of molecular medicine at UT Health San Antonio, has received two related NIH R01 grants to study uterine leiomyomas, also called uterine fibroids.

The first grant was for $1.56 million; the most recent, a five-year award for $3.8 million, was a multi-PI grant to Dr. Boyer and Ayman Al-Hendy, M.D., Ph.D., a professor of obstetrics and gynecology at the University of Illinois at Chicago.

Both awards have been made possible by a productive, ongoing collaboration with Dr. Robert Schenken and his team in the Department of OB/GYN here at UT Health San Antonio, said Dr. Boyer.

For the rest of this story, please click here.

Uncovering clues in BRCA1 breast cancer gene

Dr. Rong Li and his colleagues are changing the paradigm of how BRCA1 suppresses tumors

When Rong Li, Ph.D., transferred his laboratory to UT Health San Antonio, he finally felt he was making real progress in breast cancer research.

I was trained as a molecular biologist, and I studied the fundamental cellular processes in a lab setting, says Li, a professor of molecular medicine who left his faculty position at the University of Virginia in 2007. But I felt unsatisfied because I wanted to connect my lab findings more closely to human health.

At UT Health, he found the opportunity to collaborate with physician scientists, both at the international level and closer to home. UT Health breast oncologists Ismail Jatoi, M.D., and Richard Elledge, M.D., as well as plastic and reconstructive surgeon Dr. Howard Wang, M.D., have offered cross-disciplinary support, and some of their patients donate breast tissue samples for Lis research.

The story is continued here.

Recent Publications with High Impact Factors

*L. Hulea, *S.P. Gravel, *M. Morita, M. Cargnello, O. Uchenunu, Y.K. Im, C. Lehud, E.H. Ma, M. Leibovitch, S. McLaughlan, M.J. Blouin, M. Parisotto, V. Papavasiliou, C. Lavoie, O. Larsson, M. Ohh, T. Ferreira, C. Greenwood, G. Bridon, D. Avizonis, G. Ferbeyre, P. Siegel, R.G. Jones, W. Muller, J. Ursini-Siegel, J. St-Pierre, M. Pollak, I. Topisirovic. (2018) Translational and HIF-1-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides, Cell Metabolism. 2018 September 20. Online. *Co-First authors.

Seol JH, Holland C, Li X, Kim C, Li F, Medina-Rivera M, Eichmiller R, Gallardo IF, Finkelstein IJ, Hasty P, Shim EY, Surtees JA, Lee SE. (2018) Distinct roles of XPF-ERCC1 and Rad1-Rad10-Saw1 in replication-coupled and uncoupled inter-strand crosslink repair. Nat Commun. 2018 May 23;9(1):2025. doi:10.1038/s41467-018-04327-0. PubMed PMID: 29795289.

Patel MJ, Tripathy S, De Mukhopadhyay K, Wangjam T, Cabang AB, Morris J, Wargovich MJ. (2018) A Supercritical Co2 Extract of Neem Leaf (A. indica) and its Bioactive Liminoid, Nimbolide, Suppresses Colon Cancer in Preclinical Models by Modulating Pro-inflammatory Pathways. Mol Carcinogenesis. 2018 Apr 26. doi: 10.1002/mc.22832. [Epub ahead of print] PMID: 29697164

Park MJ, Shen H, Spaeth JM, Tolvanen JH, Failor C, Knudtson JF, McLaughlin J, Halder SK, Yang Q, Bulun SE, Al-Hendy A, Schenken RS, Aaltonen LA, Boyer TG. (2018) Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19. J Biol Chem. 2018 Mar 30; 293(13):4870-4882. doi: 10.1074/jbc.RA118.001725. Epub 2018 Feb 13.

Chen H, Shen F, Sherban A, Nocon A, Li Y, Wang H, Xu MJ, Rui X, Han J, Jiang B, Lee D, Li N, Keyhani-Nejad F, Fan JG, Liu F, Kamat A, Musi N, Guarente L, Pacher P, Gao B, Zang M. (2018) DEP domain-containing mTOR-interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute-on-chronic liver injury in alcoholic liver disease. Hepatology. 2018 Feb 19. doi: 10.1002/hep.29849. [Epub ahead of print]

Recently Awarded Grants

Early Detection of Castration-Resistant Prostate Cancer by Assessing Interactions Between Circulating Tumor Cells and Accompanying Immune CellsDOD (CDMRP-PCRP), 9/1/18, $915,000Tim Huang, Ph.D., Maria Gaczynska, Ph.D.

Mechanisms of Error Prone Repair of DNA breaksNIH – National Institute of General Medical Sciences, 8/1/18, $1,250,500Sang Eun Lee, Ph.D.

2018 Young Investigator AwardThe Max and Minnie Tomerlin Voelcker Fund, 6/30/2018, $450,000Myron Ignatius, Ph.D.

Combating protein-misfolding diseasesWilliam & Ella Owens Foundation of America, 3/1/18, $100,000Hai Rao, Ph.D.

Hypovitaminosis D promotes MED12-associated genomic instability in uterine fibroidsNIH National Institute of Child Health and Human Development, 2/15/18, $3,819,365Thomas Boyer, Ph.D.

See more here:

Molecular Medicine – Graduate School of Biomedical …

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Latest Releases:

View Scientific Abstract Oral and Poster Presentations from SNMMI’s2018 Annual Meeting.Learn More

Access synchronized slides, audio and embedded video from 100 of the most popular sessions from SNMMIs 2018 Annual Meeting.Learn More

The new Radiation Safety+ Review and Essentials program provides a comprehensive overview of all aspects of radiation safety for nuclear medicine technologists preparing to take the NMTCBs Radiation Safety Certification Examination.Learn More

CT+ Review and Essentials provides you with the comprehensive didactic education you need to succeed, whether you’re looking to buildyour general CT knowledge, or preparing to sit for the ARRT (CT) and/or NMTCB (CT) exam(s).Learn More

SNMMI’s online nuclear medicine review course coversadult and pediatric medicine, PET/CT and nuclear cardiology plus imaging protocols, interpretation and limitation.Learn More

SNMMI/ACNM MRI Case Reviews: AbdominalSNMMI and ACNM have partnered to bring you the first-ever set of online MRI teaching modules as an introduction to interpreting MRI.Learn More

Mid-Winter Meeting CT Case ReviewsThis offering provides a comprehensiveCT Case Reviewfor nuclear medicine professionals. Review and interpret up to 100 CT studies.Learn More

Annual Meeting CT/MRI Case ReviewsRecorded at the Annual Meeting, this online offering provides the opportunity to review and interpret 52 CT studies and 48 MRI case studies.Learn More

Free Journal SAM/CE accessis available exclusively for SNMMI Members. Take advantage of this great benefit and meet your certification requirements.Learn more

Fee recently reduced! The PET Online Review Workshop is designed to prepare technologists for the NMTCB’s PET Exam.Learn More

More:

Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Home | Cellular & Molecular Medicine

Sara Parker, PhD a CMM postdoctoral scholar in Dr. Gus Mouneimnes lab – together with colleagues in the departments of Neuroscience, Pharmacology, an Immunobiology have recently published a new study in the journal eNeuro entitled High Fidelity Cryopreservation and Recovery of Primary Rodent Cortical Neurons”. Cryopreservation is the process of freezing biological materials, and is used routinely for the storage of cell lines. Certain cells, however, are extremely sensitive to cryostorage, and cannot be frozen such as primary neurons isolated from mouse or rat embryos, which show extremely poor viability when subjected to standard cryopreservation methodologies. Dr. Parker and colleagues, experimenting with a specialty cryopreservation reagent designed for clinical-grade storage of human stem and primary cells, found that this reagent substantially improved the viability of cryopreserved neurons, yielding cells that were indistinguishable from freshly dissected neurons. This experimental tool not only improves efficiency and maximizes utilization of animal-sourced materials, it also facilitates greater collaboration between laboratories.

See original here:

Home | Cellular & Molecular Medicine

Molecular medicine – Wikipedia

Molecular medicine is a broad field, where physical, chemical, biological, bioinformatics and medical techniques are used to describe molecular structures and mechanisms, identify fundamental molecular and genetic errors of disease, and to develop molecular interventions to correct them.[1] The molecular medicine perspective emphasizes cellular and molecular phenomena and interventions rather than the previous conceptual and observational focus on patients and their organs.[2]

In November 1949, with the seminal paper, “Sickle Cell Anemia, a Molecular Disease”,[3] in Science magazine, Linus Pauling, Harvey Itano and their collaborators laid the groundwork for establishing the field of molecular medicine.[4] In 1956, Roger J. Williams wrote Biochemical Individuality,[5] a prescient book about genetics, prevention and treatment of disease on a molecular basis, and nutrition which is now variously referred to as individualized medicine[6] and orthomolecular medicine.[7] Another paper in Science by Pauling in 1968,[8] introduced and defined this view of molecular medicine that focuses on natural and nutritional substances used for treatment and prevention.

Published research and progress was slow until the 1970s’ “biological revolution” that introduced many new techniques and commercial applications.[9]

Some researchers separate molecular surgery as a compartment of molecular medicine.[10]

Molecular medicine is a new scientific discipline in European universities.[citation needed] Combining contemporary medical studies with the field of biochemistry, it offers a bridge between the two subjects. At present only a handful of universities offer the course to undergraduates. With a degree in this discipline the graduate is able to pursue a career in medical sciences, scientific research, laboratory work and postgraduate medical degrees.

Core subjects are similar to biochemistry courses and typically include gene expression, research methods, proteins, cancer research, immunology, biotechnology and many more. In some universities molecular medicine is combined with another discipline such as chemistry, functioning as an additional study to enrich the undergraduate program.

Go here to see the original:

Molecular medicine – Wikipedia

Molecular Medicine | USF Health

Our Mission

To Discover, apply and disseminate knowledge of the molecular basis of health and disease.

To Translate, this knowledge into innovative tools for the diagnosis, treatment and prevention of disease.

To Train, and mentor future scientists and health care professionals.

To Provide, a collegial and scholarly environment where students, faculty and staff thrive.

Read more here:

Molecular Medicine | USF Health

Molecular Medicine – Graduate School of Biomedical …

The Department of Molecular Medicine in the Institute of Biotechnology (IBT) was established in 1994 to administer a program to train graduate students at the interface of basic and clinical sciences with an emphasis on biomedical research focused on discovering the molecular mechanisms underlying human disease and to serve as a platform for the development of novel treatment or prevention approaches. To date, our program has awarded over 120 doctoral degrees. Our graduates are placed in top-tier research universities and pharmaceutical companies across the United States and Europe. Our faculty have been successful in securing tens of millions of dollars from private and federal agencies including the National Institutes of Health, the National Science Foundation, and the Department of Defense.

Now also located in the South Texas Research Facility (STRF), we offer a research-oriented, interdisciplinary program of study in the areas of cancer and aging and their prevention. Specific areas of study include: cell (and hormone) signaling, gene expression, epigenetics, cell cycle and checkpoint controls, DNA damage repair and associated stress responses, and regulated protein turnover. Under new leadership, Dr. Tim Huang is expanding our research to include a Systems approach to molecular medicine that offers students an integrated training program spanning molecular and cellular biology, quantitative biology, computational biology, and genomics.

Our goal is to educate and train the next generation of graduate students who will change the face of biomedical research and invent new ways to treat and prevent human diseases.

Molecular Medicine in the News

Graduate School Launches a New Masters in Personalized Molecular Medicine

The Masters program in Personalized Molecular Medicine (PMM) will uniquely position new graduates to join the work force with the skills necessary to participate fully in the next generation of patient-powered research and treatment. The PMM program will train students in current personalized medicine approaches as well as teach students the knowledge and skills required to explore molecular medicine pathways that will be targeted in the future to expand and refine personalized treatment strategies.

For more information, click here.

Dr. Thomas Boyer awarded NIH grants to study uterine fibroids

Thomas G. Boyer, Ph.D., professor of molecular medicine at UT Health San Antonio, has received two related NIH R01 grants to study uterine leiomyomas, also called uterine fibroids.

The first grant was for $1.56 million; the most recent, a five-year award for $3.8 million, was a multi-PI grant to Dr. Boyer and Ayman Al-Hendy, M.D., Ph.D., a professor of obstetrics and gynecology at the University of Illinois at Chicago.

Both awards have been made possible by a productive, ongoing collaboration with Dr. Robert Schenken and his team in the Department of OB/GYN here at UT Health San Antonio, said Dr. Boyer.

For the rest of this story, please click here.

Uncovering clues in BRCA1 breast cancer gene

Dr. Rong Li and his colleagues are changing the paradigm of how BRCA1 suppresses tumors

When Rong Li, Ph.D., transferred his laboratory to UT Health San Antonio, he finally felt he was making real progress in breast cancer research.

I was trained as a molecular biologist, and I studied the fundamental cellular processes in a lab setting, says Li, a professor of molecular medicine who left his faculty position at the University of Virginia in 2007. But I felt unsatisfied because I wanted to connect my lab findings more closely to human health.

At UT Health, he found the opportunity to collaborate with physician scientists, both at the international level and closer to home. UT Health breast oncologists Ismail Jatoi, M.D., and Richard Elledge, M.D., as well as plastic and reconstructive surgeon Dr. Howard Wang, M.D., have offered cross-disciplinary support, and some of their patients donate breast tissue samples for Lis research.

The story is continued here.

Recent Publications with High Impact Factors

*L. Hulea, *S.P. Gravel, *M. Morita, M. Cargnello, O. Uchenunu, Y.K. Im, C. Lehud, E.H. Ma, M. Leibovitch, S. McLaughlan, M.J. Blouin, M. Parisotto, V. Papavasiliou, C. Lavoie, O. Larsson, M. Ohh, T. Ferreira, C. Greenwood, G. Bridon, D. Avizonis, G. Ferbeyre, P. Siegel, R.G. Jones, W. Muller, J. Ursini-Siegel, J. St-Pierre, M. Pollak, I. Topisirovic. (2018) Translational and HIF-1-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides, Cell Metabolism. 2018 September 20. Online. *Co-First authors.

Seol JH, Holland C, Li X, Kim C, Li F, Medina-Rivera M, Eichmiller R, Gallardo IF, Finkelstein IJ, Hasty P, Shim EY, Surtees JA, Lee SE. (2018) Distinct roles of XPF-ERCC1 and Rad1-Rad10-Saw1 in replication-coupled and uncoupled inter-strand crosslink repair. Nat Commun. 2018 May 23;9(1):2025. doi:10.1038/s41467-018-04327-0. PubMed PMID: 29795289.

Patel MJ, Tripathy S, De Mukhopadhyay K, Wangjam T, Cabang AB, Morris J, Wargovich MJ. (2018) A Supercritical Co2 Extract of Neem Leaf (A. indica) and its Bioactive Liminoid, Nimbolide, Suppresses Colon Cancer in Preclinical Models by Modulating Pro-inflammatory Pathways. Mol Carcinogenesis. 2018 Apr 26. doi: 10.1002/mc.22832. [Epub ahead of print] PMID: 29697164

Park MJ, Shen H, Spaeth JM, Tolvanen JH, Failor C, Knudtson JF, McLaughlin J, Halder SK, Yang Q, Bulun SE, Al-Hendy A, Schenken RS, Aaltonen LA, Boyer TG. (2018) Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19. J Biol Chem. 2018 Mar 30; 293(13):4870-4882. doi: 10.1074/jbc.RA118.001725. Epub 2018 Feb 13.

Chen H, Shen F, Sherban A, Nocon A, Li Y, Wang H, Xu MJ, Rui X, Han J, Jiang B, Lee D, Li N, Keyhani-Nejad F, Fan JG, Liu F, Kamat A, Musi N, Guarente L, Pacher P, Gao B, Zang M. (2018) DEP domain-containing mTOR-interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute-on-chronic liver injury in alcoholic liver disease. Hepatology. 2018 Feb 19. doi: 10.1002/hep.29849. [Epub ahead of print]

Recently Awarded Grants

Early Detection of Castration-Resistant Prostate Cancer by Assessing Interactions Between Circulating Tumor Cells and Accompanying Immune CellsDOD (CDMRP-PCRP), 9/1/18, $915,000Tim Huang, Ph.D., Maria Gaczynska, Ph.D.

Mechanisms of Error Prone Repair of DNA breaksNIH – National Institute of General Medical Sciences, 8/1/18, $1,250,500Sang Eun Lee, Ph.D.

2018 Young Investigator AwardThe Max and Minnie Tomerlin Voelcker Fund, 6/30/2018, $450,000Myron Ignatius, Ph.D.

Combating protein-misfolding diseasesWilliam & Ella Owens Foundation of America, 3/1/18, $100,000Hai Rao, Ph.D.

Hypovitaminosis D promotes MED12-associated genomic instability in uterine fibroidsNIH National Institute of Child Health and Human Development, 2/15/18, $3,819,365Thomas Boyer, Ph.D.

See the original post here:

Molecular Medicine – Graduate School of Biomedical …